Ilaris

 
Gilenya first high efficacy oral therapy approved in Japan for the prevention of relapse and delay of progression of physical disability in adults with multiple sclerosis (MS) Ilaris the first drug approved in Japan for the treatment of cryopyrin-associated periodic syndrome (CAPS), a rare and debilitating auto inflammatory disease Approvals demonstrate ongoing Novartis commitment to bringing innovative treatments to patients in Japan